Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates

Published on March 20, 2026
BERKELEY HEIGHTS, N.J.—Kalaris Therapeutics, Inc. (Nasdaq: KLRS), a biopharmaceutical company focused on developing clinical-stage treatments for common retinal diseases, has released its financial results and provided business updates for the full year ended December 31, 2025. The company reported a net loss of $43.4 million for full-year 2025, a reduction from the net loss of $69.2 million recorded for the year ended December 31, 2024. “This past year was truly transformational for Kalaris,” said Andrew Oxtoby, CEO of Kalaris Therapeutics.
Continue reading on website
Other news

Glaukos Announces Commercial Availability of Epioxa for Incision-Free Keratoconus Care

March 20, 2026
ALISO VIEJO, Calif.—Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medtech company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced the commercial availability of Epioxa HD/Epioxa, an advancement in corneal cross-linking for the treatment of keratoconus. Epioxa is now commercially available for ordering directly from Gl

Cherry Optical Makes Investment in U.S.-Based Lens Manufacturing

March 20, 2026
GREEN BAY, Wis.—Cherry Optical Lab (COL), a family-owned, independent wholesale optical laboratory, has announced a major series of expansions across its coating, surfacing, finishing and employment operations. This month, the company completed an update to its surfacing equipment that included replacing previously used Schneider surface blockers, generators, and polishers with Schneider’s Modulo